Alternative oral exemestane formulation: Improved dissolution and permeation

Development of optimized self-nano-emulsifying drug delivery systems (SNEDDS) of carvedilol with enhanced bioavailability potential

“…This renders the drug unsuitable for traditional methods of bioavailability enhancement like micronization, solid dispersions using hydrophilic carriers and block-copolymers, complexation with water-soluble carrier(s), etc. (Patel et al, 2008;Vogt et al, 2008;Yavuz et al, 2010). All these techniques yield limited fruition when the drug exhibits low bioavailability, owing to metabolism by the cytochrome P450 family of enzymes present in the gut enterocytes and liver hepatocytes, instability in gastrointestinal (GI) fluids, restricted intestinal permeability, and/ or P-glycoprotein (P-gp) efflux (de Smidt et al, 2004;Sha et al, 2005;Koga et al, 2006;Constantinides & Wasan, 2007;Hauss, 2007;Singh et al, 2009a).…”

The Preparation of Preserved Shallot Powders and a Pilot Study of the Antioxidative Effect of Their Aqueous Extracts on the Formation of Hydroxyl Radical Species

“…The findings for the antioxidative effects of shallot aqueous extracts reveal that in the ribose degradation assay all three shallot aqueous extracts appear to increase the amount of the Meta-analysis has shown that shallot reduces the risk of gastric cancer, but only if a large amount of shallot is consumed [11]. The solubility and bioavailability of exemestane, an irreversible aromatase inhibitor, has been found to greatly improve in powder and tablet form [20], so the beneficial effects of shallot powders prepared using these protocols are increased if the shallot powder is dissolved in water or other types of solvents. The longterm health benefits of shallot aqueous extracts due to their antioxidative effect on human diseases deserves further investigation.…”

Molecular Buckets: Cyclodextrins for Oral Cancer Therapy

“…In this context, different anticancer drugs have been studied including paclitaxel [44], danazol [45], noscapine [46] or exemestane [47,48]. One of the first studies was conducted by Kikuchi and collaborators in 1987.…”

“…The absolute bioavailability was significantly higher with the solution (80%) than with the suspension (8%) [50]. Similarly, Yavuz and collaborators prepared inclusion complexes between exemestane (EXE) and MCD, HPCD or HPCD [47]. The complexes between EXE and MβCD displayed a high ability to increase the permeability of the anticancer drug to cross biological membranes.…”